Jeil Pharma Holdings Balance Sheet Health
Financial Health criteria checks 5/6
Jeil Pharma Holdings has a total shareholder equity of ₩436.3B and total debt of ₩149.4B, which brings its debt-to-equity ratio to 34.2%. Its total assets and total liabilities are ₩881.2B and ₩444.9B respectively.
Key information
34.2%
Debt to equity ratio
₩149.39b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩48.04b |
| Equity | ₩436.29b |
| Total liabilities | ₩444.87b |
| Total assets | ₩881.15b |
Recent financial health updates
These 4 Measures Indicate That Jeil Pharma Holdings (KRX:002620) Is Using Debt Extensively
Feb 27
Jeil Pharma Holdings (KRX:002620) Has A Somewhat Strained Balance Sheet
Nov 23
Recent updates
Is Jeil Pharma Holdings Inc (KRX:002620) A Smart Choice For Dividend Investors?
Mar 25These 4 Measures Indicate That Jeil Pharma Holdings (KRX:002620) Is Using Debt Extensively
Feb 27What Percentage Of Jeil Pharma Holdings Inc (KRX:002620) Shares Do Insiders Own?
Jan 23Jeil Pharma Holdings (KRX:002620) Has Compensated Shareholders With A 56% Return On Their Investment
Dec 28Jeil Pharma Holdings (KRX:002620) Has A Somewhat Strained Balance Sheet
Nov 23Financial Position Analysis
Short Term Liabilities: A002620's short term assets (₩387.7B) exceed its short term liabilities (₩376.7B).
Long Term Liabilities: A002620's short term assets (₩387.7B) exceed its long term liabilities (₩68.1B).
Debt to Equity History and Analysis
Debt Level: A002620's net debt to equity ratio (23.2%) is considered satisfactory.
Reducing Debt: A002620's debt to equity ratio has increased from 14.3% to 34.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A002620 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A002620 has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 9% each year.